American Society of Hematology

Fig. 2.

$Fig. 2. Detection of Fas ligand in serum from patients by Western blot analysis. / Serum samples from 9 patients with LGL leukemia (lanes 1-9) and 1 healthy donor (lane 10) were fractionated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis and subjected to Western immunoblotting with an anti-Fas ligand antibody that recognizes the soluble form of Fas ligand. Arrow indicates the position of the 26-kd soluble Fas ligand protein. The levels of soluble Fas ligand in the serum determined by ELISA are shown in the upper panel. Each blot is representative of 3 experiments.$

Detection of Fas ligand in serum from patients by Western blot analysis.

Serum samples from 9 patients with LGL leukemia (lanes 1-9) and 1 healthy donor (lane 10) were fractionated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis and subjected to Western immunoblotting with an anti-Fas ligand antibody that recognizes the soluble form of Fas ligand. Arrow indicates the position of the 26-kd soluble Fas ligand protein. The levels of soluble Fas ligand in the serum determined by ELISA are shown in the upper panel. Each blot is representative of 3 experiments.

This Feature Is Available To Subscribers Only